

# Journal of Visualized Experiments

## Generation of topically transgenic rats by in utero electroporation and in vivo bioluminescence screening

--Manuscript Draft--

<b>Manuscript Number:</b>	JoVE50146R5
<b>Full Title:</b>	Generation of topically transgenic rats by in utero electroporation and in vivo bioluminescence screening
<b>Article Type:</b>	Methods Article - JoVE Produced Video
<b>Corresponding Author:</b>	Carsten Korth Heinrich Heine University Düsseldorf Düsseldorf, NRW GERMANY
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Heinrich Heine University Düsseldorf
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Sandra Vomund
<b>First Author Secondary Information:</b>	
<b>Order of Authors Secondary Information:</b>	
<b>Abstract:</b>	<p>In utero electroporation (IUE) is a technique which allows genetic modification of cells in the brain for investigating neuronal development. So far, the use of IUE for investigating behavior or neuropathology in the adult brain has been limited by insufficient methods for monitoring of IUE transfection success by non-invasive techniques in postnatal animals.</p> <p>For the present study, E16 rats were used for IUE. After intraventricular injection of the nucleic acids into the embryos, positioning of the tweezer electrodes was critical for targeting either the developing cortex or the hippocampus.</p> <p>Ventricular co-injection and electroporation of a luciferase gene allowed monitoring of the transfected cells postnatally after intraperitoneal luciferin injection in the anesthetized live P7 pup by in vivo bioluminescence, using an IVIS Spectrum device with 3D quantification software.</p> <p>Area definition by bioluminescence could clearly differentiate between cortical and hippocampal electroporations and detect a signal longitudinally over time up to 5 weeks after birth. This imaging technique allowed us to select pups with a sufficient number of transfected cells assumed necessary for triggering biological effects and, subsequently, to perform behavioral investigations at 3 month of age. As an example, this study demonstrates that IUE with the human full length DISC1 gene into the rat cortex led to amphetamine hypersensitivity. Co-transfected GFP could be detected in neurons by post mortem fluorescence microscopy in cryosections indicating gene expression present at <math>\geq 6</math> months after birth.</p> <p>We conclude that postnatal bioluminescence imaging allows evaluating the success of transient transfections with IUE in rats. Investigations on the influence of topical gene manipulations during neurodevelopment on the adult brain and its connectivity are greatly facilitated. For many scientific questions, this technique can supplement or even replace the use of transgenic rats and provide a novel technology for behavioral neuroscience.</p>
<b>Corresponding Author E-Mail:</b>	ckorth@uni-duesseldorf.de
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
<b>Order of Authors:</b>	Sandra Vomund
	Tamar Sapir

	Orly Reiner
	Angelica de Souza Silva
	Carsten Korth
<b>Author Comments:</b>	<p>Journal of Visualized Experiments Editor-in-Chief</p> <p>Düsseldorf, 23.4.13</p> <p>Dear Dr. Zhao Chen,</p> <p>please find enclosed the revised version of our manuscript "Generation of topically transgenic rats by in utero electroporation and in vivo bioluminescence screening" where we have integrated the comments from the reviewers, as far as it was possible. Please find below a detailed response-to-reviewers letter.</p> <p>Thank you very much Regards</p> <p>Carsten Korth</p> <p>Response to Reviewers JOVE50146R3, 23.4.13</p> <p>Reviewer #1: Manuscript Summary: This manuscript describes a very useful improvement of the standard in utero electroporation technique. By co-electroporating a plasmid that encodes luciferase, cells which have been successfully electroporated with the sequence of interest can be tracked in vivo (this feature is very important) by intraperitoneally injecting a luciferase substrate to the pups and performing a bioluminescence scan. This provides a very useful tool that will find wide interest among researchers using in utero electroporation. Application of the technique is illustrated with a specific experiment using DISC1.</p> <p>→ We thank reviewer for this positive review</p> <p>Major Concerns: None</p> <p>Minor Concerns: None</p> <p>Additional Comments to Authors: On section 2.8.1, "checkmark" instead of "ceckmark" (spelling typo)</p> <p>→ This typo has been corrected on page 6.</p> <p>Reviewer #2: Manuscript Summary: In this manuscript, the authors describe an exciting method for in vivo screening of in utero electroporation (IUE) efficiency and general location. This is a valuable contribution to the field, as performing downstream behavioral analyses following IUE can be quite expensive, and there is great value in knowing these variables prior to engaging in behavioral analyses.</p> <p>Major Concerns: 1. The postmortem analysis of the single brain compared to the in vivo luciferase signal on the same brain is highly valuable. The same verification process should be performed for figure 5, showing that the cortical versus hippocampal localization of</p>

luciferase activity in vivo is confirmed at the dissected brain level and in sections.

→ We have performed the early experiment depicted in Figure 6 on principal grounds, to establish that there is a gross overlap between factual localization of IUE neurons visualized by GFP fluorescence and the amount of bioluminescence signal obtained by IVIS recording. However, when we noted that GFP was not useful for in vivo quantitation of IUE neurons (see Figure 6D, and first paragraph on page 15), we did not co-transfect GFP any longer. We agree that the proposed experiment is interesting but argue that neither does the limited time allowance for revising this manuscript permit including this additional experiment, nor is the experiment essential for the filmed visual protocol proposed in this paper.

2. It is important to describe your exact criteria for including an animal in this particular behavioral assay. For example, do you need to pass a certain threshold level of signal? If so, what is that threshold. Also, in the discussion it would be worth commenting more about subject selection based on imaging - for example, certainly the behavioral assay chosen may well determine the level and region of the brain that should be targeted.

→ A sentence concerning the selection of animals has been included in the Discussion section (Page 14).

On page 2, last sentence of the 3rd paragraph of the introduction, we have mentioned that the reason for choosing amphetamine challenge test was that in a similar experiment in mice, Niwa et al. (ref. 18) had used this behavioral test successfully. We have added a sentence to the Discussion on page 18 where we state that the match between the IUE region and the behavioral test is dependent on the scientific question.

Minor Concerns:

1. The Figure numbering is all confused between the text and Figures/figure legends. Also, Figures should be numbered based on their appearance in the text. Also, there is no image for Figure 1. Figure legend for Figure 6 has the wrong title.

→ Figure numbering in the text has been corrected throughout. The title of Figure 6 has been changed.

2. In the Intro, the authors mention that "...fluorescence signals could not be detected in postnatal stages in vivo...". Please add the detail of the method used for this. Same comment for "representative results" section.

→ Please see trouble shooting paragraph "GFP-fluorescence detection of the pups" on page 15 where details of the used methods have now been included.

Below an example of a test for fluorescence detection:  
This is the same animal shown bioluminescence detection in Figure 6. For Fluorescence measurements of GFP two filter pairs (excitation/emission: 465/520 and 500/540) have been chosen, with an exposure time of 3 min.

3. In the abstract, I recommend highlighting the ability to longitudinally image these animals over time, which is quite valuable.

→ Due to the limited number of allowed words for the abstract, it is not possible to include more details about that. But the word "longitudinally over time" has been included (page 2).

4. please spell check the document

→ The entire document has been spell-checked.

5. It would be very valuable if the authors could comment in the discussion about the limit of detection for this system. Specifically, can they provide a rough estimate for the number of cells that are required to be hit in order to detect luciferase signal.

→ In the discussion on page 14 a few sentences about signal strength in the live imaging and counted GFP-labeled cells, has been included.

Additional Comments to Authors:  
N/A

Reviewer #3:

Manuscript Summary:

In this paper Vomund et al examined the use of in vivo postnatal bioluminescent imaging technique to monitor the rat cerebral cortex and hippocampus, target regions where certain cells are overexpressed by luciferase expression plasmids via in utero electroporation during embryonic stages. The authors reported that postnatal intraperitoneal injection of D-luciferin induces luciferase reaction, which is detectable by bioluminescence live imaging system at least up to postnatal day 35. The author also confirmed the feasibility of in utero electroporation to test long lasting effects of gene targeting on behaviors, by showing that overexpression of human DISC1 elicited an increase of amphetamine induced hyperlocomotion. Overall, monitoring in utero gene manipulation by in vivo postnatal imaging is very innovative and potentially useful, although there are some limitations which need to be addressed for publication.

Major Concerns:

Page 5, The author described that in utero electroporation at embryonic day 16 targeted the cells in layer II-IV of the cerebral cortex. However, gene targeting via in utero electroporation seems to be more layer-specific. For instance, in the case of mouse cerebral cortex, cells targeted at E14.5 are mostly differentiated at layers II/III.

→ This has been corrected on page 4 (section 1.3.5). Basically, we replaced the previous statement with the more neutral statement "upper cortical layers" quoting the paper by LoTurco et al. (ref. 23) where a similar statement was used accounting for the lack of consensus in this particular question.

Page 12, 14, Niwa et al reported the behavioral effect of DISC1 silencing in the mouse bilateral prefrontal cortex, whereas the author tested overexpression of DISC1 in the unilateral cortical area. Is there any rationale to test unilateral, not bilateral manipulation?

→ Reasons and advantages to choose unilateral electroporation have been integrated in the discussion on page 14.

Figure 7, Although the data discerned from the bioluminescence image in Figure 6 suggest that sufficient number of cells are manipulated via in utero electroporation, the number of GFP-labeled cells in the Figure 7 looks very small. Please replace it with a more representative image to show if results are consistent.

→ We increased the quality of the picture so that the GFP-positive neurons are now better visible. The picture is very representative.

Tables in Page 16, 28, Although the authors listed reagents of shRNA for Dab silencing in the tables, it seems to have no data showing the knockdown effect of Dab (reelin signal transducer?) via in utero electroporation in the text.

→ We apologize for the accidental insertion of "Dab1shRNA" vector information and have corrected for DISC1-overexpression vector information on page 16.

Minor Concerns:

Page 3, the use of in utero electroporation for studies of neuropsychiatric disorders has been extensively discussed in the recent review article (Taniguchi et al, Neuroscientist 2012), which is better to be included as a reference.

→ The named Taniguchi et al. reference has been added in the introduction (ref. 19).

Page 16, catalog number of D-Amphetamine is missing.



→ catalog number for D-amphetamine was added on page 15

Tables in Page17, 28, 5mm of Tweezer electrode is CUY650P5, not CUY650P7.  
Please correct it.

→ Has been corrected on page 16.



Prof. Carsten Korth, MD PhD  
Institute for Neuropathology  
Heinrich Heine University Düsseldorf  
Moorenstrasse 5  
40225 Düsseldorf  
Tel +49- 211- 811 6153  
Fax +49- 211- 811 7804  
Email ckorth@uni-duesseldorf.de

**Journal of Visualized Experiments**

**Editor-in-Chief**

Düsseldorf, 23.4.13

Dear Dr. Zhao Chen,

please find enclosed the revised version of our manuscript "Generation of topically transgenic rats by *in utero* electroporation and *in vivo* bioluminescence screening" where we have integrated the comments from the reviewers, as far as it was possible. Please find below a detailed response-to-reviewers letter.

Thank you very much

Regards

Carsten Korth

## Response to Reviewers JOVE50146R3, 23.4.13

### Reviewer #1:

#### *Manuscript Summary:*

This manuscript describes a very useful improvement of the standard in utero electroporation technique. By co-electroporating a plasmid that encodes luciferase, cells which have been successfully electroporated with the sequence of interest can be tracked in vivo (this feature is very important) by intraperitoneally injecting a luciferase substrate to the pups and performing a bioluminescence scan. This provides a very useful tool that will find wide interest among researchers using in utero electroporation. Application of the technique is illustrated with a specific experiment using DISC1.

→ We thank reviewer for this positive review

#### *Major Concerns:*

None

#### *Minor Concerns:*

None

#### *Additional Comments to Authors:*

On section 2.8.1, "checkmark" instead of "ceckmark" (spelling typo)

→ This typo has been corrected on page 6.

### Reviewer #2:

#### *Manuscript Summary:*

In this manuscript, the authors describe an exciting method for in vivo screening of in utero electroporation (IUE) efficiency and general location. This is a valuable contribution to the field, as performing downstream behavioral analyses following IUE can be quite expensive, and there is great value in knowing these variables prior to engaging in behavioral analyses.

#### *Major Concerns:*

1. The postmortem analysis of the single brain compared to the in vivo luciferase signal on the same brain is highly valuable. The same verification process should be performed for figure 5, showing that the cortical versus hippocampal localization of luciferase activity in vivo is confirmed at the dissected brain level and in sections.

→ We have performed the early experiment depicted in Figure 6 on principal grounds, to establish that there is a gross overlap between factual localization of IUE neurons visualized by GFP fluorescence and the amount of bioluminescence signal obtained by IVIS recording. However, when we noted that GFP was not useful for in vivo quantitation of IUE neurons (see Figure 6D, and first paragraph on page 15), we did not co-transfect GFP any longer. We agree that the proposed experiment is interesting but argue that neither does the limited time allowance for revising this manuscript permit including this additional experiment, nor is the experiment essential for the filmed visual protocol proposed in this paper.

2. It is important to describe your exact criteria for including an animal in this particular behavioral assay. For example, do you need to pass a certain threshold level of signal? If so, what is that threshold. Also, in the discussion it would be worth commenting more about subject selection based on imaging - for example, certainly the behavioral assay chosen may well determine the level and region of the brain that should be targeted.

→ A sentence concerning the selection of animals has been included in the Discussion section (Page 14).

On page 2, last sentence of the 3rd paragraph of the introduction, we have mentioned that the reason for choosing amphetamine challenge test was that in a similar experiment in mice, Niwa et al. (ref. 18) had used this behavioral test successfully. We have added a sentence to the Discussion on page 18 where we state that the match between the IUE region and the behavioral test is dependent on the scientific question.

Minor Concerns:

1. The Figure numbering is all confused between the text and Figures/figure legends. Also, Figures should be numbered based on their appearance in the text. Also, there is no image for Figure 1. Figure legend for Figure 6 has the wrong title.


→ Figure numbering in the text has been corrected throughout. The title of Figure 6 has been changed.

2. In the Intro, the authors mention that "...fluorescence signals could not be detected in postnatal stages in vivo...". Please add the detail of the method used for this. Same comment for "representative results" section.

→ Please see trouble shooting paragraph "GFP-fluorescence detection of the pups" on page 15 where details of the used methods have now been included.

Below an example of a test for fluorescence detection:

This is the same animal shown bioluminescence detection in Figure 6. For Fluorescence measurements of GFP two filter pairs (excitation/emission: 465/520 and 500/540) have been chosen, with an exposure time of 3 min.



3. In the abstract, I recommend highlighting the ability to longitudinally image these animals over time, which is quite valuable.

→ Due to the limited number of allowed words for the abstract, it is not possible to include more details about that. But the word "longitudinally over time" has been included (page 2).

4. please spell check the document

→ The entire document has been spell-checked.

5. It would be very valuable if the authors could comment in the discussion about the limit of detection for this system. Specifically, can they provide a rough estimate for the number of cells that are required to be hit in order to detect luciferase signal.

→ In the discussion on page 14 a few sentences about signal strength in the live imaging and counted GFP-labeled cells, has been included.

**Reviewer #3:**

Manuscript Summary:

In this paper Vomund et al examined the use of in vivo postnatal bioluminescent imaging technique to monitor the rat cerebral cortex and hippocampus, target regions where certain cells are overexpressed by luciferase expression plasmids via in utero electroporation during embryonic stages. The authors reported that postnatal intraperitoneal injection of D-luciferin induces luciferase reaction, which is detectable by bioluminescence live imaging system at least up to postnatal day 35. The author also confirmed the feasibility of in utero electroporation to test long lasting effects of gene targeting on behaviors, by showing that overexpression of human DISC1 elicited an increase of amphetamine induced hyperlocomotion. Overall, monitoring in utero gene manipulation by in vivo postnatal imaging is very innovative and potentially useful, although there are some limitations which need to be addressed for publication.

Major Concerns:

Page 5, The author described that in utero electroporation at embryonic day 16 targeted the cells in layer II-IV of the cerebral cortex. However, gene targeting via in utero electroporation seems to be more layer-specific. For instance, in the case of mouse cerebral cortex, cells targeted at E14.5 are mostly differentiated at layers II/III.

→ This has been corrected on page 4 (section 1.3.5). Basically, we replaced the previous statement with the more neutral statement "upper cortical layers" quoting the paper by LoTurco et al. (ref. 23) where a similar statement was used accounting for the lack of consensus in this particular question.

Page 12, 14, Niwa et al reported the behavioral effect of DISC1 silencing in the mouse bilateral prefrontal cortex, whereas the author tested overexpression of DISC1 in the unilateral cortical area. Is there any rationale to test unilateral, not bilateral manipulation?

→ Reasons and advantages to choose unilateral electroporation have been integrated in the discussion on page 14.

Figure 7, Although the data discerned from the bioluminescence image in Figure 6 suggest that sufficient number of cells are manipulated via in utero electroporation, the number of GFP-labeled cells in the Figure 7 looks very small. Please replace it with a more representative image to show if results are consistent.

→ We increased the quality of the picture so that the GFP-positive neurons are now better visible. The picture is very representative.

Tables in Page 16, 28, Although the authors listed reagents of shRNA for Dab silencing in the tables, it seems to have no data showing the knockdown effect of Dab (reelin signal transducer?) via in utero electroporation in the text.

→ We apologize for the accidental insertion of "Dab1shRNA" vector information and have corrected for DISC1-overexpression vector information on page 16.

Minor Concerns:

Page 3, the use of in utero electroporation for studies of neuropsychiatric disorders has been extensively discussed in the recent review article (Taniguchi et al, Neuroscientist 2012), which is better to be included as a reference.

→ The named Taniguchi et al. reference has been added in the introduction (ref. 19).

Page 16, catalog number of D-Amphetamine is missing.

→ catalog number for D-amphetamine was added on page 15

Tables in Page17, 28, 5mm of Tweezer electrode is CUY650P5, not CUY650P7. Please correct it.

→ Has been corrected on page 16.

## **Generation of topically transgenic rats by *in utero* electroporation and *in vivo* bioluminescence screening**

**Authors:** Sandra Vomund, Tamar Sapir, Orly Reiner, Angelica de Souza Silva, and Carsten Korth

### **Authors: institution(s)/affiliation(s) for each author:**

Sandra Vomund  
Department of Neuropathology  
Medical School Düsseldorf, Germany  
[sandra.vomund@uni-duesseldorf.de](mailto:sandra.vomund@uni-duesseldorf.de)

Tamar Sapir  
Department of Molecular Genetics  
Weizmann Institute for Science, Israel  
[tamar.sapir@weizmann.ac.il](mailto:tamar.sapir@weizmann.ac.il)

Orly Reiner  
Department of Molecular Genetics  
Weizmann Institute for Science, Israel  
[orly.reiner@weizmann.ac.il](mailto:orly.reiner@weizmann.ac.il)

Maria A. de Souza Silva  
Center of Behavioral Neuroscience  
University of Düsseldorf  
[desouza@uni-duesseldorf.de](mailto:desouza@uni-duesseldorf.de)

Carsten Korth  
Department of Neuropathology  
Medical School Düsseldorf, Germany  
[ckorth@uni-duesseldorf.de](mailto:ckorth@uni-duesseldorf.de)

**Corresponding author:** Carsten Korth

### **Keywords:**

*In utero* electroporation, *in vivo* bioluminescence imaging, Luciferase, Disrupted-in-schizophrenia-1 (DISC1),

### **Short Abstract:**

Genes can be manipulated during development of the cortex or the hippocampus of the rat via *in utero* electroporation (IUE) at E16, to enable fast and targeted modifications in neuronal connectivity for later studies of behavior or neuropathology in adult animals. Postnatal *in vivo* imaging for control of IUE success is performed by bioluminescence of activating co-transfected luciferase.

### **Long Abstract:**

*In utero* electroporation (IUE) is a technique which allows genetic modification of cells in the brain for investigating neuronal development. So far, the use of IUE for investigating behavior or neuropathology in the adult brain has been limited by insufficient methods for monitoring of IUE transfection success by non-invasive techniques in postnatal animals.



For the present study, E16 rats were used for IUE. After intraventricular injection of the nucleic acids into the embryos, positioning of the tweezer electrodes was critical for targeting either the developing cortex or the hippocampus.

Ventricular co-injection and electroporation of a luciferase gene allowed monitoring of the transfected cells postnatally after intraperitoneal luciferin injection in the anesthetized live P7 pup by *in vivo* bioluminescence, using an IVIS Spectrum device with 3D quantification software.

Area definition by bioluminescence could clearly differentiate between cortical and hippocampal electroporations and detect a signal longitudinally over time up to 5 weeks after birth. This imaging technique allowed us to select pups with a sufficient number of transfected cells assumed necessary for triggering biological effects and, subsequently, to perform behavioral investigations at 3 month of age. As an example, this study demonstrates that IUE with the human full length *DISC1* gene into the rat cortex led to amphetamine hypersensitivity. Co-transfected GFP could be detected in neurons by *post mortem* fluorescence microscopy in cryosections indicating gene expression present at  $\geq 6$  months after birth.

We conclude that postnatal bioluminescence imaging allows evaluating the success of transient transfections with IUE in rats. Investigations on the influence of topical gene manipulations during neurodevelopment on the adult brain and its connectivity are greatly facilitated. For many scientific questions, this technique can supplement or even replace the use of transgenic rats and provide a novel technology for behavioral neuroscience.

### Introduction:

The development of the *in utero* electroporation (IUE) method which allows a modulation of gene expression in the developing brain, has been a break-through since it enabled studying neurodevelopment with relative ease.<sup>1-7</sup> Changes in expression levels of a target gene in a specific brain region during embryonic and/or perinatal development in rodents were demonstrated to critically influence neuronal proliferation, migration, arborization, and connectivity.<sup>8-10</sup>

Schizophrenia is a complex mental illness with acute and chronic symptoms that has been related to neurodevelopmental abnormalities<sup>11,12</sup> and therefore many of the identified candidate genes for schizophrenia are investigated for potential modulating effects on neurodevelopment, like for example for the *disrupted-in-schizophrenia-1* (*DISC1*) gene<sup>13-15</sup>.

Brain development is regulated by genetic factors and their interactions with environment which play roles in pre-, peri- and postnatal developmental periods. One major genetic risk factor for various behavioral disorders is the *DISC1*<sup>16</sup> gene. *DISC1* knockdown leads to migration defects in mice<sup>13,17</sup>, and manipulation of *DISC1* expression in the developing cortex by IUE has been shown to impact behavior of adult mice<sup>18</sup>.

Manipulating brain gene expression by IUE has several advantages<sup>19</sup> over the generation of transgenic animal lines. First, gene expression within areas of interest is achieved within weeks to months rather than several generations of breeding transgenic rodent lines. Second, compensatory mechanisms during early development that may shield phenotypes in germline-engineered animals<sup>20</sup> are avoided. Third, through targeting only a specific cell population or specific area of the brain, migration or proliferation differences can be directly compared with the non-

mutant or control contralateral side if unilateral electroporations are chosen. On the other hand, IUE does not have the accuracy of promoter-driven cre/lox-induced timing of expression and only a subpopulation of the cells in a certain area is targeted leading to a mosaic kind of gene expression pattern.

For many experimental applications in adult rodents, a transient transfection of a limited number of cells in a brain region may be sufficient, or even desired, so that the major advantage of stable, germline-transgenic rodents is negligible. In fact, IUE is useful to investigate whether some abnormally developed cells may affect a whole network of cells or circuitry. Another advantage may be the ability to demonstrate non cell-autonomous effects of a gene due to the mosaic nature of the hit. Furthermore, the generation of transgenic and knockout rats is still in its infancy and the use of IUE in this species for studying aberrant brain development consequences is of high interest.

So far, a major obstacle of using IUE for investigating the intervention consequences in those animals as adults is the lack of monitoring electroporation success. So far, GFP-co-transfected fluorescent neurons in the live newborn rat pups could not be detected under a suitable binocular fluorescence microscope or with the fluorescence imaging of the IVIS Spectrum.

To overcome this obstacle, we co-transfected a luciferase reporter gene and performed bioluminescence live imaging of pups by 3-dimensional (3D) quantitation of the IUE brain area.

As an example for demonstrating the applicability of this method in a later functional assay testing the neurodevelopmental genetic manipulation, a co-injection of plasmids containing human DISC1, luciferase, and GFP into the lateral ventricle of rat embryos<sup>3</sup> followed by electroporation with a tweezer electrode was performed. While fluorescence signals could not be detected in postnatal stages *in vivo*, a solid bioluminescence signal derived from luciferin metabolism by co-transfected luciferase gene was detected up to five weeks after birth. 3D-measurements of the electroporated brain area allowed quantification whereby pups with insufficient or misplaced electroporation were identified from the outset, thus, enabling the assignment of IUE animals (gene of interest and scrambled control) to experimental groups with matched electroporated brain areas of low variability. The use of adult IUE rats in behavioral paradigms was demonstrated as an example of the usefulness of this protocol.

#### **Protocol:**

Parts of the protocol foreseen as part of the video article of JOVE are highlighted in yellow

All animal experiments were authorized by the responsible Landesministerium für Natur, Umwelt und Verbraucherschutz (LANUV NRW; 87-51.05.2010.A301) in accordance with National and European legislation.

##### **1.) *in utero* electroporation**

This method has been described in detail in JOVE for the rat by Walantus et al.<sup>3</sup>, as well as Rice et al.<sup>4</sup> and is here summarized only briefly. A litter size of 6-8 pups yields a good outcome. There should be at least two non-electroporated embryos in order to increase the overall survival rate (see below).

1.1) Prepare DNA-Mixture that contains 1.5 µg/µL of target-Plasmid (shRNA: pENTR-U6; Invitrogen, Eugene, OR / DISC1 overexpression: pCAX<sup>21</sup>), 0.5 µg/µL Luciferase containing Plasmid (pCAX), 0.5 µg/µL GFP containing plasmid (pCAGGS<sup>22</sup>) in 1x PBS solution stained light blue with Fast Green Dye.

1.2) Prepare injection needles out of glass capillaries with a Needle Pipette Puller.

1.3) Anesthetize a pregnant rat 16 days after fertilization in an isoflurane chamber.

1.3.1) Upon anesthesia, place the rat in a supine position on a 37°C-warmed operation table with breathing mask connected to the anesthesia device, using oxygen setting at 0.4 L/min and isoflurane at 1.8 %.

1.3.2.) After shaving the abdomen, disinfect the shaved area three times with kodan Tinktur forte (an alcohol-based disinfectant).

1.3.3) Cover the rat with sterile cloths, exposing only the shaved operation field.

1.4) Perform *in utero* electroporation .

1.4.1) Cut the abdomen with a scissor along the *linea alba* (~ 2 cm).

1.4.2) Expose the uterine horns carefully with a ring forceps.

1.4.3) Take care to keep the uterus wall wet with warmed sterile PBS during the whole surgery.

1.4.4) Inject DNA solution with a thin glass needle into one of the lateral ventricle of the embryos.

1.4.5) Place the 7 mm electrode around the head of the embryo. To hit a cell population of upper cortical layers, perform the IUE at E16<sup>23</sup> and position the positive electrode on the hemisphere above the injected ventricle with a slight dorsal/lateral tendency. To target hippocampal cells change the positive electrode placement to the opposite side than the injected ventricle with lateral to slightly dorsal direction. (Figure 1).

1.4.6) Perform electroporation by five 50 ms pulses at 55 V with 950 ms breaks with a square wave pulse electroporator.

1.4.7) Spare the first embryo at the vaginal end of each uterus horn in order to increase the chances of survival of all embryos.

1.4.8) Put the uterus horns back into the mother rat.

1.4.9) Stich the abdominal wall up with an absorbable vicryl surgical suture material.

1.4.10) Close the skin with the vicryl suture material or with suture clips.

1.5.1) Place the mother rat back into the home cage and keep it warm for 2-3 h.

1.5.2) Hold the rats alone in their home cage in the animal facility room and feed *ad libitum*. They give birth between E22-24.

1.5.3) Keep the rat pups with their mother for three weeks and separate them afterwards by gender.

## **2.) Bioluminescence live imaging of the enzymatic luciferase reaction**

This method is used to analyze the position and to quantify of the *in utero* transfected cells. Co-electroporated firefly luciferase cDNA is translated into active luciferase, which upon metabolizing D-luciferin to oxyluciferin, emits a photon (Figure 2). The resulting luminescence can be detected in the brains of positive electroporated young rats in an IVIS Spectrum up to the age of around 35 days postnatally (Figure 4). In the present study, the luciferase assay and bioluminescence imaging was performed starting at P7. This time point was chosen to allow mother and pups to recover from birth stress. When initially working with the pups at P0, pup survival was severely affected in that the pups were found dead or eaten by the mother. Initially, rat pups with successful electroporation are identified by a 2D-bioluminescence picture with an exposure time of three minutes. Subsequently, positive pups are used for creating 3D images in order to specify the location of the electroporated area.

2.1) Dilute D-luciferin sodium salt in PBS to a concentration of 15 mg/mL and sterilize it by filtration through a sterile syringe filter

2.2) Weigh the pups


2.3) Take the pup in one hand with the abdomen on top and stretch the abdomen slightly. Inject 10  $\mu$ L/g of body weight of luciferin solution intraperitoneal. For older and more agile ones, pre-anaesthetize the pups with isoflurane in the induction chamber before injecting the luciferin.

2.4) Turn on the isoflurane influx of the XGI-8 Gas Anesthesia System within the IVIS Spectrum with 3 % isoflurane

2.5) Put the snout of the animal into the glass nose cones of the Anesthesia System

2.6) Hold the animal in a prone position until it is in deep anesthesia (2-3 min). Then reduce the isoflurane influx to 1.5 %

2.7) Choose a 2D-bioluminescence measurement to select positive pups from the whole litter.  
Use the following settings



2.7.1) Set a checkmark on Photograph with medium binning and F/Stop at 8, the camera takes a photo from above after starting the measurement

2.7.2) Set Excitation filter: block

2.7.3) Set Emission filter: open


2.7.4) Set Binning to medium

2.7.5) Set F/Stop at 1

2.7.6) Set Stage level A

2.7.7) Set luminescence exposure time to 180 sec.

2.8) For creation of 3D pictures in order to better quantify the electroporated area from the positive pups, use the following DLIT settings for firefly luciferase



2.8.1) Set a checkmark on Photograph; the camera takes a photo from above after starting the measurement

2.8.2) Set a checkmark on Structure, the surface of the animal is scanned by the IVIS prior the bioluminescence measurement

2.8.3) Use following Emission filters and exposure time settings


Until the age of two weeks:

Emission filter 1: 590 nm, exposure time 300 sec

Emission filter 2: 600 nm, exposure time 240 sec  
 Emission filter 3: 620 nm, exposure time 180 sec  
 Emission filter 4: 640 nm, exposure time 120 sec

For rats older than P20

Emission filter 1: 600 nm, exposure time 300 sec  
 Emission filter 2: 620 nm, exposure time 300 sec  
 Emission filter 3: 640 nm, exposure time 300 sec



Due to the decrease in signal strength in older animals, the exposure time is enlarged for the three best emission filters.

#### 2.8.4) Set Stage level B

#### 2.8.5) Set Binning to medium.

#### 2.8.6) Set F/Stop at 1

2.9) After measurement, mark the rats by an earhole code to differentiate them from each other and to match them to the IVIS Live Imaging pictures



2.10) At the end of the measurement procedure, turn off isoflurane influx and keep the rat on the warmed plate for some minutes before returning it to its cage.

### 3.) Analysis of bioluminescence images


The generation of 3D images, 3D movies and the quantification of the volume of the signal source is made by the Living Image software pre-installed on the IVIS Spectrum.

#### 3.1) Generation of 3D images


3.1.1) First, reconstruct a surface topography, therefore set threshold between 20 and 30 %.










3.1.2) Start DLIT 3D reconstruction with an image threshold of 10 % for each wavelength.





3.2.1) Create 3D movies by using the animate button within the 3D toolbar.

3.2.2) Choose different orientations of the 3D image, as well as zooming views as key frames and press the 'Record' button, recording the changeover from one position/orientation to another.



#### 4.) Behavioral testing

Behavioral testing was performed in order to determine whether IUE-mediated gene manipulations in the rat might initiate long-term effects that persist into adulthood. In the present particular case, the effect of transient, unilateral full length human DISC1 cortical overexpression after IUE was investigated by testing locomotion in an open field (OF), with and without a low dose of amphetamine, as a specific test for dopamine-related behavior<sup>24</sup>. In a similar procedure performed by Niwa et al. in IUE mice using DISC1 knockdown, IUE mice but not controls showed hypersensitivity to amphetamine<sup>18</sup>.

Rats that were *in utero* electroporated with a DISC1 overexpressing vector were held under laboratory conditions with 12 h light from 7 am to 7 pm and were fed *ad libitum*. At 3 months of age, rats underwent behavioral testing.

For quantifying locomotion as a readout of amphetamine effects, an open-field of a Tru Scan activity system situated in a sound- and light-isolated was used. This system measures the duration time and distance the animal moves, time and distance spent in the margin or center of the open field, as well as rearing behavior<sup>25</sup>.

##### 4.1) On the first day, test after saline injection

###### 4.1.1) Weigh the animals.

###### 4.1.2) Inject intraperitoneally 1 $\mu$ L/g body weight of a saline solution (1 x PBS).

###### 4.1.3) Right after the injection, put the animal into the open-field and start the measurement of the TruScan system. Record-for 15 min and subdivide data into 3 x 5 min parts.

###### 4.1.4) Put the animal back into its home cage.

#### 4.2) Second day, test on amphetamine injection

##### 4.2.1) Weigh the animals.

4.2.2) Inject intraperitoneally 1  $\mu\text{L/g}$  body weight of a 0.5 mg/mL amphetamine solution.

4.2.3) Right after the injection put the animal into the open-field and start the measurement of the TruScan system. Record for 15 min and subdivide data into 3 x 5 min parts.

4.2.4) Return the animal to its home cage

4.3) Analyze locomotion and rearing behavior generated by specific Tru Scan software. Create Graphs with GraphPad (Prism) and calculate statistics by SPSS Statistics software.

#### **Representative Results:**

Figure 3 shows live imaging measurements of three rat pups at P7 after the injection of 150 mg luciferin/kg body weight. Differences of signal strength indicating the variability in the IUE efficiency of the IUE are visible. Strong bioluminescence signals were recorded until P36 (Figure 4). In Figure 5, the ability to define cortical (Figure 5A, C) and hippocampal (Figure 5B, D) electroporation by bioluminescence imaging are depicted. Correlation of the bioluminescence signal (Figure 7A) with its fluorescence signal after skull removal (Figure 7B) and the corresponding GFP-electroporated cells in cryosectioned brain (Figure 8) at P14 are depicted in Figures 6-8. Of note, there was no detection of a fluorescence signal in live rats at any time point.

*In vivo* bioluminescence imaging enables approximate discrimination of different electroporated brain areas by 2D (Figure 5 A and B) which is greatly improved with the DLIT program of the IVIS Spectrum software generating 3D images (Figure 5C and D). In the shown examples, electroporation of the prefrontal cortex and hippocampal could be distinguished. It should be noted that while aiming to electroporate the hippocampus, some progenitor cells for the cortex lying dorsal of the hippocampus can also be hit (Figure 7). Figure 5 demonstrates that plasmid-transfected, GFP-expressing cells are detectable at  $\geq 3$  months after birth. Rats unilaterally *in utero* electroporated with pCAX vector into the cortex and subsequently overexpressing full length human DISC1 were investigated for both spontaneous and amphetamine-induced hyperactivity as adults. Rats electroporated with pCAX-DISC1 were hypersensitive to a low dose of amphetamine. These rats moved significantly more after amphetamine treatment than after to saline injection, whereas control animals did not (Figure 10).

#### **Figures:**

**Figure 1** Scheme of electrode position for A) cortex electroporation and B) hippocampal electroporation; green = injected DNA-Mix within the ventricle.

**Figure 2** Luciferase reaction.

**Figure 3** Luminescence measurement of P7 rats after injection of 150 mg/kg body weight luciferine; exposure time 180 sec; A) rat with no luminescence signal; B) rat with a weak bioluminescence signal; C) rat with a strong luminescence signal.

**Figure 4** Time line of consecutive bioluminescence measurements of the same rat after injection of 150 mg/kg luciferine demonstrating a large time window where IUE success can be detected.

**Figure 5** Illustration of differences between cortical and hippocampal electroporation at P7. A) & B) 2D pictures; C) & D) 3D pictures; A) & C) from cortex; B) & D) from hippocampus.

**Figure 6** Illustration of E16 hippocampal electroporation of a rat pup at P14 A) 2D-picture of bioluminescence B) 3D illustration of the bioluminescence signal C) dissected brain with bioluminescence signal D) brain with GFP epi-fluorescence signal

**Figure 7** Detail of a fluorescence picture from a 20  $\mu$ m cryo section of the same P14 rat brain electroporated with GFP containing plasmid and luciferase vector, nuclei staining with Dapi; CA1-3 = Cornu Ammonis 1-3; DG = Dentate Gyrus; FC = Fasciolarum cinereum

**Video 1** 3D animation of a hippocampus electroporated rat at P14

**Figure 8** Amphetamine test scheme; 8) scheme of experiment, first day saline injection before the 15 min trial, 24 h later amphetamine injection before testing in the open field chamber.

**Figure 9** Amphetamine test. Bar graph showing moved distance (in cm) of the animal recorded by a TrueScan system over 15 min. White bars = control group; striped bars = DISC1 overexpressing group; control group n = 10; DISC1 overexpression group n = 11; ANOVA: geno\*treatment p = 0.043; T-Test for total time saline vs amphetamine n.s.= not significant  $p_{\text{control}} = 0.172$ ,  $p_{\text{DISC1}} = 0.001$ .

### Discussion:

Our study demonstrates that IUE is suited to generate adult rats with neurons expressing a transgene in a selective area of the brain and that, as a result of this intervention, these animals exhibit changes in behavior indicating functionality of the performed manipulation. In this study, as an example, rats overexpressing DISC1 unilaterally in a small part of the prefrontal cortex showed hypersensitivity towards amphetamine (Figure 9).

Selecting rats for electroporation success by *in vivo* bioluminescence imaging was effective in controlling for the inherent variability of IUE cell transfection and was applied to generate groups with a homogenous IUE area of low inter-subject variability for later investigations.

In this study, we were unable to select electroporated pups from the litter by detection of the co-electroporated GFP-induced fluorescence in the newborn animal, even though at the same time and in the same animal a bioluminescence signal of the equally co-electroporated luciferase could be detected after luciferin injection (Figure

6), and the GFP expressing neurons were still present in the brain at an age of six months. We conclude that, in the rat, the luciferase/luciferin reaction is well-suited to differentiate animals with successful electroporated brains (Figure 3).

The quantitative monitoring of IUE success relates to the strength of the bioluminescence signal which is measured by the counts of photons within the same exposure time (Figure 3) and corresponds to the enzymatic activity of co-expressed luciferase. Small bioluminescence signals are detectable by 100-200 counts of photons, and, at a radiance of  $\sim 1e^4$  photons/sec/cm<sup>2</sup>/steradian show 1000 to 2000 GFP-stained cells in the histology in the 6 months old rat brain. The highest signal displayed a radiance of up to  $\sim 5e^6$  photons/sec/cm<sup>2</sup>/steradian and  $\sim 64000$  counts. In the Sprague Dawley rat strain used, we observed a weakening of the bioluminescence signal longitudinally with increasing age and the signal disappeared beyond the age of P35 (Figure 4). At this point, we do not know whether either the transient, plasmid vector-based expression of luciferase decreases, or if the bioluminescence signal losses due to increasing brain mass, or both are the causes for the disappearing signal. For the present functional assay in the adult rats, the selection for behavioral studies was merely made based on the location of the signal, but not by bioluminescence signal strength.

Even though 3D quantitative bioluminescence monitoring allowed differentiation between different electroporated areas (Figure 5), its accurateness was limited for cells located in the depth dimension of the brain. Figure 6 shows an example of a hippocampal electroporation where the bioluminescence measurement in the 2D and the 3D picture indicated a good positioning of the electroporation. In the dissected post mortem brain, a GFP-fluorescence signal was detected at about the same position as the bioluminescence signal, indicating correct targeting of the hippocampus. But histology shows that also cells in the cortex dorsal of the hippocampus had been targeted (Figure 7). This indicates that the bioluminescence assay is a useful tool to detect positive, IUE pups and also to have an idea of the electroporated area, but, ultimately, imaging cannot replace *post mortem* histology to exactly localize positively targeted cells.

Our demonstration indicates promise for the application of the IUE technology to generate subtle targeted manipulations of cortical or hippocampal brain regions to simulate aberrances in cortical migration or other neurodevelopmental defects that may influence the adult animal. While bilateral electroporation<sup>26</sup> has the advantage of a likely bigger effect on behavior, there is also more mortality of embryos. Unilateral electroporation was chosen in order to compare the two hemispheres with one as an internal control, as well as for showing that even IUE manipulating in an unilateral, small region is sufficient to change behavior. IUE-induced changes in connectivity or architecture between neurons may thus be induced without evoking a lesion and the required match of the to-be-IUE-manipulated region with the appropriate behavioral test is dependent on the scientific question.

### **Trouble shooting:**

#### **Reduced litter size**

There are several suggestions regarding increasing the survival rate of IUE pups. First, the use of very thin glass capillaries during electroporation in order to minimize tissue lesion is recommended. Second, do not electroporate the first embryo at the vaginal end of each uterus horn: death of the first-born embryo increases the

chances of an abort of all other embryos. Third, after birth, mother rats often kill part of their progeny due to perinatal stress. In order to reduce additional stress, do not start with the live imaging right after birth, but wait for seven days.

### **GFP-fluorescence detection of the pups**

At one week after birth, no signal of fluorescence by either using live binocular fluorescence microscopic imaging or fluorescence imaging with the IVIS Spectrum (epifluorescence and transfluorescence modes; for GFP excitation/emission: 465/520 and 500/540). It is possible that both, the limited transmission of short wavelength excitation and emission light through tissue like the skull and the high autofluorescence background of the skin prevent using fluorescence under the described conditions in the rat. As shown in Figure 6, the luciferase signal in the living animal can also be detected in the dissected brain (without skull) and there, also a fluorescence signal is detectable (Figure 6D).

### **Differentiation of bioluminescence in closely spaced brain areas**

Even in the 3D illustration the location of the bioluminescence area cannot be predicted to 100%. Especially cells on top of or below of the predicted area can also be accidentally targeted and transfected. The exact position has to be controlled by post mortem (fluorescence) histology (see Figure 7).

### **Disclosures:**

The authors of this study do not have financial interest in this study or have been sponsored by industry.

### **Acknowledgments:**

Our thanks to Tracy Young-Pearse and Atsushi Kamiya for providing plasmids.

This work was funded by NEURON-ERANET DISCover to O.R. and C.K. (BMBF 01EW1003), DFG (Ko 1679/3-1; GRK1033) to C.K., and (DE 792/2-4) to M.A.S.S.

### **Table of specific reagents:**

<b>Reagent name</b>	<b>Company</b>	<b>Catalog number</b>	<b>Comments (optional)</b>
Dulbecco's Phosphate-Buffered Saline (PBS)	Invitrogen	14190-250	without calcium, without magnesium
D-luciferin, sodium salt	SynChem OHG, Germany	BC218	CAS number: 103404-75-7 substrate for firefly-luciferase
Fast Green FCF	Sigma Aldrich, USA	F7258-25G	CAS: 2353-45-9
D-Amphetamine	Sigma Aldrich, USA	A 5880	CAS: 51-63-8



kodan Tinktur forte	Schülke & Mayr GmbH, Germany	104 005	
---------------------	------------------------------	---------	--

**Table of recipes:**

Number	Buffer name	Content	Comments (optional)
1	DNA-Mixture for DISC-1 overexpressing	1.5 µg/µL pCAX humanDISC-1, 0.5 µg/µL pCAX-luciferase, 10x PBS (10 %) Fast Green Dye (0,5 %) add H <sub>2</sub> O	100 µL of the mixture are enough for ~5 IUE
2	DNA-Mixture for control	0,75 µg/µL control shRNA1, 0,75 µg/µL control shRNA2, 0.5 µg/µL pCAX-luciferase, 0.5 µg/µL pCAGGS-GFP 10x PBS (10 %) Fast Green Dye (0,5 %) add H <sub>2</sub> O	100 µL of the mixture are enough for ~5 IUE
3	Fast green Dye	10 mg/mL Fast Green FCF in ddH <sub>2</sub> O	
4	D-luciferin solution	15 mg/mL D-luciferin, sodium salt in PBS	
5	Amphetamine solution	0.5 mg/mL D-Amphetamine in PBS	

**Table of material and equipment:**

Material / product	Company	state	Comments (optional)
Glass capillaries	Sutter Instrument	Novato, California, USA	borosilicate glass O.D.:1 mm, I.D.: 0.78mm
Needle Pipette Puller	David Kopf Instruments	Tujunga, California, USA	
Tweezer electrode	Nepa Gene CO., LTD.	Shioyaki, Ichikawa, Chiba, Japan	7 mm in diameter platinum disc electrodes (CUY650P7)
Surgical Scissors – sharp	Fine Science Tools	Heidelberg, Germany	Straight, 12 cm (14002-12)
Ring Forceps	Fine Science Tools	Heidelberg, Germany	2.2 mm ID, 3 mm OD (11021-12)
Square wave pulse electroporator (CUY21SC)	Nepa Gene CO., LTD.	Shioyaki, Ichikawa, Chiba, Japan	(CUY21SC)
Vicryl surgical suture material	Ethicon	Norderstedt, Germany	3-0; 2 Ph. Eur;

Wound Clip Applicator	Fine Science Tools	Heidelberg, Germany	Reflex 9 mm (12032-09)
Syringe filter	VWR	Darmstadt, Germany	0.45 µm cellulose acetate
IVIS Spectrum	Caliper Life Science / PerkinElmer	Waltham, Massachusetts USA	
XGI-8 Gas Anesthesia System	PerkinElmer	Waltham, Massachusetts USA	
Open-field	Coulbourn Instruments	Allentown, USA	(40 x 40 x 39 cm)
Tru Scan activity system	Coulbourn Instruments	Allentown, USA	


## References:




- 1 Saito, T. & Nakatsuji, N. Efficient gene transfer into the embryonic mouse brain using in vivo electroporation. *Developmental biology* **240**, 237-246 (2001).
- 2 Fukuchi-Shimogori, T. & Grove, E. A. Neocortex patterning by the secreted signaling molecule FGF8. *Science* **294**, 1071-1074, doi:10.1126/science.1064252 (2001).
- 3 Walantus, W., Elias, L. & Kriegstein, A. In utero intraventricular injection and electroporation of E16 rat embryos. *J Vis Exp*, 236, doi:10.3791/236 (2007).
- 4 Rice, H., Suth, S., Cavanaugh, W., Bai, J. & Young-Pearse, T. L. In utero electroporation followed by primary neuronal culture for studying gene function in subset of cortical neurons. *J Vis Exp*, doi:10.3791/2103 (2010).
- 5 Takahashi, M. Manipulating gene expressions by electroporation in the developing brain of mammalian embryos. *Differentiation* **70**, 155 (2002).
- 6 Tabata, H. & Nakajima, K. Efficient in utero gene transfer system to the developing mouse brain using electroporation: visualization of neuronal migration in the developing cortex. *Neuroscience* **103**, 865-872 (2001).
- 7 Nakahira, E. & Yuasa, S. Neuronal generation, migration, and differentiation in the mouse hippocampal primordium as revealed by enhanced green fluorescent protein gene transfer by means of in utero electroporation. *J Comp Neurol* **483**, 329-340, doi:10.1002/cne.20441 (2005).
- 8 Young-Pearse, T. L. *et al.* A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **27**, 14459-14469, doi:10.1523/JNEUROSCI.4701-07.2007 (2007).
- 9 Niwa, M. *et al.* Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. *Neuron* **65**, 480-489 (2010).
- 10 Sapir, T. *et al.* Accurate balance of the polarity kinase MARK2/Par-1 is required for proper cortical neuronal migration. *The Journal of neuroscience : the official journal*


- of the Society for Neuroscience* **28**, 5710-5720, doi:10.1523/JNEUROSCI.0911-08.2008 (2008).
- 11 Weinberger, D. R. From neuropathology to neurodevelopment. *Lancet* **346**, 552-557 (1995).
  - 12 Murray, R. M. & Lewis, S. W. Is schizophrenia a neurodevelopmental disorder? *British medical journal (Clinical research ed)* **295**, 681-682 (1987).
  - 13 Kamiya, A. *et al.* A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. *Nat Cell Biol* **7**, 1167-1178, doi:10.1038/ncb1328 (2005).
  - 14 Miyoshi, K. *et al.* Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. *Mol Psychiatry* **8**, 685-694, doi:10.1038/sj.mp.4001352 (2003).
  - 15 Mao, Y. *et al.* Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3 $\beta$ /beta-catenin signaling. *Cell* **136**, 1017-1031, doi:10.1016/j.cell.2008.12.044 (2009).
  - 16 Millar, J. K. *et al.* Disruption of two novel genes by a translocation co-segregating with schizophrenia. *Hum Mol Genet* **9**, 1415-1423 (2000).
  - 17 Steinecke, A., Gampe, C., Valkova, C., Kaether, C. & Bolz, J. Disrupted-in-Schizophrenia 1 (DISC1) is necessary for the correct migration of cortical interneurons. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **32**, 738-745, doi:10.1523/JNEUROSCI.5036-11.2012 (2012).
  - 18 Niwa, M. *et al.* Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. *Neuron* **65**, 480-489, doi:10.1016/j.neuron.2010.01.019 (2010).
  - 19 Taniguchi, Y., Young-Pearse, T., Sawa, A. & Kamiya, A. In utero electroporation as a tool for genetic manipulation in vivo to study psychiatric disorders: from genes to circuits and behaviors. *The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry* **18**, 169-179, doi:10.1177/1073858411399925 (2012).
  - 20 Bai, J. *et al.* RNAi reveals doublecortin is required for radial migration in rat neocortex. *Nat Neurosci* **6**, 1277-1283, doi:10.1038/nn1153 (2003).
  - 21 Osumi, N. & Inoue, T. Gene transfer into cultured mammalian embryos by electroporation. *Methods* **24**, 35-42, doi:10.1006/meth.2001.1154 (2001).
  - 22 Momose, T. *et al.* Efficient targeting of gene expression in chick embryos by microelectroporation. *Development, growth & differentiation* **41**, 335-344 (1999).
  - 23 LoTurco, J., Manent, J. B. & Sidiqi, F. New and improved tools for in utero electroporation studies of developing cerebral cortex. *Cereb Cortex* **19 Suppl 1**, i120-125, doi:10.1093/cercor/bhp033 (2009).
  - 24 Featherstone, R. E., Kapur, S. & Fletcher, P. J. The amphetamine-induced sensitized state as a model of schizophrenia. *Progress in neuro-psychopharmacology & biological psychiatry* **31**, 1556-1571 (2007).
  - 25 Pum, M., Carey, R. J., Huston, J. P. & Muller, C. P. Dissociating effects of cocaine and d-amphetamine on dopamine and serotonin in the perirhinal, entorhinal, and prefrontal cortex of freely moving rats. *Psychopharmacology* **193**, 375-390, doi:10.1007/s00213-007-0791-2 (2007).
  - 26 dal Maschio, M. *et al.* High-performance and site-directed in utero electroporation by a triple-electrode probe. *Nature communications* **3**, 960, doi:10.1038/ncomms1961 (2012).





\*Figure

[Click here to download Figure: figure 2.eps](#)


















B



\*Figure

[Click here to download Figure: figure 7brain slices new.eps](#)




Table of recipes:

Number	Buffer name	Content	Comments (optional)
1	DNA-Mixture for <b>DISC-1 overexpressing</b>	1.5 µg/µL <b>pCAX humanDISC-1</b> , 0.5 µg/µL pCAX-luciferase, 10x PBS (10 %) Fast Green Dye (0,5 %) add H <sub>2</sub> O	100 µL of the mixture are enough for ~5 IUE
2	DNA-Mixture for control	0,75 µg/µL control shRNA1, 0,75 µg/µL control shRNA2, 0.5 µg/µL pCAX-luciferase, 0.5 µg/µL pCAGGS-GFP 10x PBS (10 %) Fast Green Dye (0,5 %) add H <sub>2</sub> O	100 µL of the mixture are enough for ~5 IUE
3	Fast green Dye	10 mg/mL Fast Green FCF in ddH <sub>2</sub> O	
4	D-luciferin solution	15 mg/mL D-luciferin, sodium salt in PBS	
5	Amphetamine solution	0.5 mg/mL D-Amphetamine in PBS	

Table of material and equipment:

Material / product	Company	state	Comments (optional)
glass capillaries	Sutter Instrument	Novato, California, USA	borosilicate glass O.D.:1 mm, I.D.: 0.78mm
Needle Pipette Puller	David Kopf Instruments	Tujunga, California, USA	
Tweezer electrode	Nepa Gene CO., LTD.	Shioyaki, Ichikawa, Chiba, Japan	5 mm in diameter platinum disc electrodes ( <i>CUY650P7</i> )
Surgical Scissors – sharp	Fine Science Tools	Heidelberg, Germany	Straight, 12 cm (14002-12)
Ring Forceps	Fine Science Tools	Heidelberg, Germany	2.2 mm ID, 3 mm OD (11021-12)
Square wave pulse electroporator ( <i>CUY21SC</i> )	Nepa Gene CO., LTD.	Shioyaki, Ichikawa, Chiba, Japan	( <i>CUY21SC</i> )
vicryl surgical suture material	Ethicon	Norderstedt, Germany	3-0; 2 Ph. Eur;
Wound Clip Applicator	Fine Science	Heidelberg, Germany	Reflex 9 mm (12032-09)

	Tools		
IVIS <sup>®</sup> Spectrum	Caliper Life Science / PerkinElmer	Waltham, Massachusetts USA	
XGI-8 Gas Anesthesia System	PerkinElmer	Waltham, Massachusetts USA	
Tru Scan activity system	Coulbourn Instruments	Allentown, USA	





17 Sellers Street  
Cambridge, MA 02139  
tel. +1.617.945.9051  
www.JoVE.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Generation of topically transgenic rats...

Author(s):

Vomund, Sapir, Reiner, de Souza, Korth

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the

Oh



## ARTICLE AND VIDEO LICENSE AGREEMENT

Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

**5. Grant of Rights in Video – Standard Access.** This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

**6. Grant of Rights in Video – Open Access.** This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

**7. Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict

shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

**8. Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

**9. Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

**10. JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including,

*dc*



## ARTICLE AND VIDEO LICENSE AGREEMENT

without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or

damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

### AUTHOR:

Name:

Carsten Korte MD PhD

Department:

Neuropathology


Institution:

University Düsseldorf

Article Title:

Generation of topically transgenic mice

Signature:



Date:

April 25th, 2013

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy as a PDF to the JoVE submission site upon manuscript submission (preferred);
- 2) Fax the document to +1.866.381.2236; or
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 17 Sellers St / Cambridge, MA 02139

For questions, please email [editorial@jove.com](mailto:editorial@jove.com) or call +1.617.945.9051.

MS # (internal use):

## Response to Reviewers JOVE50146R3, 23.4.13

### Reviewer #1:

#### *Manuscript Summary:*

This manuscript describes a very useful improvement of the standard in utero electroporation technique. By co-electroporating a plasmid that encodes luciferase, cells which have been successfully electroporated with the sequence of interest can be tracked in vivo (this feature is very important) by intraperitoneally injecting a luciferase substrate to the pups and performing a bioluminescence scan. This provides a very useful tool that will find wide interest among researchers using in utero electroporation. Application of the technique is illustrated with a specific experiment using DISC1.

→ We thank reviewer for this positive review

#### *Major Concerns:*

None

#### *Minor Concerns:*

None

#### *Additional Comments to Authors:*

On section 2.8.1, "checkmark" instead of "ceckmark" (spelling typo)

→ This typo has been corrected on page 6.

### Reviewer #2:

#### *Manuscript Summary:*

In this manuscript, the authors describe an exciting method for in vivo screening of in utero electroporation (IUE) efficiency and general location. This is a valuable contribution to the field, as performing downstream behavioral analyses following IUE can be quite expensive, and there is great value in knowing these variables prior to engaging in behavioral analyses.

#### *Major Concerns:*

1. The postmortem analysis of the single brain compared to the in vivo luciferase signal on the same brain is highly valuable. The same verification process should be performed for figure 5, showing that the cortical versus hippocampal localization of luciferase activity in vivo is confirmed at the dissected brain level and in sections.

→ We have performed the early experiment depicted in Figure 6 on principal grounds, to establish that there is a gross overlap between factual localization of IUE neurons visualized by GFP fluorescence and the amount of bioluminescence signal obtained by IVIS recording. However, when we noted that GFP was not useful for in vivo quantitation of IUE neurons (see Figure 6D, and first paragraph on page 15), we did not co-transfect GFP any longer. We agree that the proposed experiment is interesting but argue that neither does the limited time allowance for revising this manuscript permit including this additional experiment, nor is the experiment essential for the filmed visual protocol proposed in this paper.



2. It is important to describe your exact criteria for including an animal in this particular behavioral assay. For example, do you need to pass a certain threshold level of signal? If so, what is that threshold. Also, in the discussion it would be worth commenting more about subject selection based on imaging - for example, certainly the behavioral assay chosen may well determine the level and region of the brain that should be targeted.

→ A sentence concerning the selection of animals has been included in the Discussion section (Page 14).

On page 2, last sentence of the 3rd paragraph of the introduction, we have mentioned that the reason for choosing amphetamine challenge test was that in a similar experiment in mice, Niwa et al. (ref. 18) had used this behavioral test successfully. We have added a sentence to the Discussion on page 18 where we state that the match between the IUE region and the behavioral test is dependent on the scientific question.

#### Minor Concerns:

1. The Figure numbering is all confused between the text and Figures/figure legends. Also, Figures should be numbered based on their appearance in the text. Also, there is no image for Figure 1. Figure legend for Figure 6 has the wrong title.


→ Figure numbering in the text has been corrected throughout. The title of Figure 6 has been changed.

2. In the Intro, the authors mention that "...fluorescence signals could not be detected in postnatal stages in vivo...". Please add the detail of the method used for this. Same comment for "representative results" section.

→ Please see trouble shooting paragraph "GFP-fluorescence detection of the pups" on page 15 where details of the used methods have now been included.

Below an example of a test for fluorescence detection:

This is the same animal shown bioluminescence detection in Figure 6. For Fluorescence measurements of GFP two filter pairs (excitation/emission: 465/520 and 500/540) have been chosen, with an exposure time of 3 min.



3. In the abstract, I recommend highlighting the ability to longitudinally image these animals over time, which is quite valuable.

→ Due to the limited number of allowed words for the abstract, it is not possible to include more details about that. But the word "longitudinally over time" has been included (page 2).

4. please spell check the document

→ The entire document has been spell-checked.

5. It would be very valuable if the authors could comment in the discussion about the limit of detection for this system. Specifically, can they provide a rough estimate for the number of cells that are required to be hit in order to detect luciferase signal.

→ In the discussion on page 14 a few sentences about signal strength in the live imaging and counted GFP-labeled cells, has been included.

Additional Comments to Authors:

N/A

### **Reviewer #3:**

Manuscript Summary:

In this paper Vomund et al examined the use of in vivo postnatal bioluminescent imaging technique to monitor the rat cerebral cortex and hippocampus, target regions where certain cells are overexpressed by luciferase expression plasmids via in utero electroporation during embryonic stages. The authors reported that postnatal intraperitoneal injection of D-luciferin induces luciferase reaction, which is detectable by bioluminescence live imaging system at least up to postnatal day 35. The author also confirmed the feasibility of in utero electroporation to test long lasting effects of gene targeting on behaviors, by showing that overexpression of human DISC1 elicited an increase of amphetamine induced hyperlocomotion. Overall, monitoring in utero gene manipulation by in vivo postnatal imaging is very innovative and potentially useful, although there are some limitations which need to be addressed for publication.

Major Concerns:

Page 5, The author described that in utero electroporation at embryonic day 16 targeted the cells in layer II-IV of the cerebral cortex. However, gene targeting via in utero electroporation seems to be more layer-specific. For instance, in the case of mouse cerebral cortex, cells targeted at E14.5 are mostly differentiated at layers II/III.

→ This has been corrected on page 4 (section 1.3.5). Basically, we replaced the previous statement with the more neutral statement "upper cortical layers" quoting the paper by LoTurco et al. (ref. 23) where a similar statement was used accounting for the lack of consensus in this particular question.

Page 12, 14, Niwa et al reported the behavioral effect of DISC1 silencing in the mouse bilateral prefrontal cortex, whereas the author tested overexpression of DISC1

in the unilateral cortical area. Is there any rationale to test unilateral, not bilateral manipulation?

→ Reasons and advantages to choose unilateral electroporation have been integrated in the discussion on page 14.

Figure 7, Although the data discerned from the bioluminescence image in Figure 6 suggest that sufficient number of cells are manipulated via in utero electroporation, the number of GFP-labeled cells in the Figure 7 looks very small. Please replace it with a more representative image to show if results are consistent.

→ We increased the quality of the picture so that the GFP-positive neurons are now better visible. The picture is very representative.

Tables in Page16, 28, Although the authors listed reagents of shRNA for Dab silencing in the tables, it seems to have no data showing the knockdown effect of Dab (reelin signal transducer?) via in utero electroporation in the text.

→ We apologize for the accidental insertion of "Dab1shRNA" vector information and have corrected for DISC1-overexpression vector information on page 16.

Minor Concerns:

Page3, the use of in utero electroporation for studies of neuropsychiatric disorders has been extensively discussed in the recent review article (Taniguchi et al, Neuroscientist 2012), which is better to be included as a reference.

→ The named Taniguchi et al. reference has been added in the introduction (ref. 19).

Page 16, catalog number of D-Amphetamine is missing.

→ catalog number for D-amphetamine was added on page 15

Tables in Page17, 28, 5mm of Tweezer electrode is CUY650P5, not CUY650P7. Please correct it.

→ Has been corrected on page 16.